Bedell Frazier Investment Counselling’s Celldex Therapeutics CLDX Stock Holding History

Bedell Frazier Investment Counselling’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,349	Closed	-$1.02M	–	47
2015 Q4	$1.02M	Buy	4,349 +361	+9%	+$78.7K	0.51%	32
2015 Q3	$631K	Buy	3,988 +203	+5%	+$57.5K	0.36%	36
2015 Q2	$1.43M	Buy	3,785 +812	+27%	+$322K	0.57%	40
2015 Q1	$1.24M	Sell	2,973 -1,082	-27%	-$387K	0.52%	41
2014 Q4	$1.11M	Sell	4,055 -244	-6%	-$60.7K	0.54%	40
2014 Q3	$836K	Sell	4,299 -75	-2%	-$16.3K	0.39%	40
2014 Q2	$1.07M	Buy	+4,374	New	+$988K	0.54%	35

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Bedell Frazier Investment Counselling's CLDX Position: Q1 2016 in Review

Bedell Frazier Investment Counselling sold out of Celldex Therapeutics (CLDX) in Q1 2016, closing a stake of 4,349 shares — an estimated $1.02M sold.

Bedell Frazier Investment Counselling first reported a position in CLDX in Q2 2014 and held it in 7 quarters. The position peaked at $1.43M in Q2 2015. 145 funds tracked by Wall St. Rank hold CLDX as of Q1 2016.

Bedell Frazier Investment Counselling reported no remaining Celldex Therapeutics position as of Q1 2016 after selling out during the quarter.
Bedell Frazier Investment Counselling sold 4,349 Celldex Therapeutics shares in Q1 2016, an estimated $1.02M.
Bedell Frazier Investment Counselling first reported a position in Celldex Therapeutics in Q2 2014 and held it in 7 quarters.
Bedell Frazier Investment Counselling's Celldex Therapeutics position peaked at $1.43M in Q2 2015.
145 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2016.

Based on Bedell Frazier Investment Counselling's 13F filing for Q1 2016, filed 10 May 2016.